{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:36:37Z","timestamp":1792784197695,"version":"4.5.0"},"reference-count":114,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Research Impact Fund of the Research Grants Council","award":["R4035-19"],"award-info":[{"award-number":["R4035-19"]}],"id":[{"id":"https:\/\/ror.org\/00jb20j87","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005847","name":"Health and Medical Research Fund","doi-asserted-by":"crossref","award":["08191436,08191356, 09202866"],"award-info":[{"award-number":["08191436,08191356, 09202866"]}],"id":[{"id":"10.13039\/501100005847","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Direct Grant for Research","award":["2024.173, 2024.078, 2025.077"],"award-info":[{"award-number":["2024.173, 2024.078, 2025.077"]}]},{"name":"IdeaBooster Fund","award":["IDBF24MED11"],"award-info":[{"award-number":["IDBF24MED11"]}]},{"name":"Research Grant from Hong Kong Institute of Allergy"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Allergen-specific immunotherapy (AIT) is currently the only disease-modifying treatment for food allergies. The most extensively studied form of AIT is oral immunotherapy, in which an increasing dose of specific food allergen is gradually introduced to allergic patients for immune system \u201cre-education.\u201d It has been demonstrated to effectively achieve desensitization, raising the threshold for inducing allergic reactions after allergen ingestion. However, lengthy dosing schedules and the occurrence of severe adverse events have impeded the adoption and compliance of oral immunotherapy. In recent years, extensive efforts in developing novel platforms have been directed to heighten the immunogenicity and lower the allergenicity of AIT, in hopes of increasing its efficacy and safety. Certain vaccine candidates have been investigated in preclinical and clinical trials. In this review, we aim to summarize the state-of-the-art technology of next-generation AIT vaccines for food allergy and explore research gaps in the field that warrant further investigation. We adopted a \u2018Cargo-Truck-Lubricant\u2019 analogy to illustrate the components of AIT, corresponding to modified allergens, carriers delivering the allergens, and the immunomodulators fostering the delivery. While most studies focused mainly on peanut allergy, novel AITs for other food allergies were still in preclinical stages. Future directions point towards optimization and the clinical translation of next-generation AIT vaccines to maximize the therapeutic outcome and minimize risks.<\/jats:p>","DOI":"10.1007\/s12016-025-09104-8","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:29:12Z","timestamp":1761128952000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Next-Generation Allergen-Specific Immunotherapy for Food Allergy"],"prefix":"10.1007","volume":"68","author":[{"given":"Joyce Z. X.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason K. C.","family":"Sit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicki Y. H.","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka Hou","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick S. C.","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting Fan","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine Y. Y.","family":"Wai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"issue":"1","key":"9104_CR1","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1542\/peds.2011-0204","volume":"128","author":"RS Gupta","year":"2011","unstructured":"Gupta RS, Springston EE, Warrier MR, Smith B, Kumar R, Pongracic J et al (2011) The prevalence, severity, and distribution of childhood food allergy in the United States. Pediatrics 128(1):e9-17","journal-title":"Pediatrics"},{"issue":"2","key":"9104_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s11882-020-0898-7","volume":"20","author":"CM Warren","year":"2020","unstructured":"Warren CM, Jiang J, Gupta RS (2020) Epidemiology and burden of food allergy. Curr Allergy Asthma Rep 20(2):6","journal-title":"Curr Allergy Asthma Rep"},{"issue":"3","key":"9104_CR3","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.jaci.2011.01.039","volume":"127","author":"NJ Osborne","year":"2011","unstructured":"Osborne NJ, Koplin JJ, Martin PE, Gurrin LC, Lowe AJ, Matheson MC et al (2011) Prevalence of challenge-proven IgE-mediated food allergy using population-based sampling and predetermined challenge criteria in infants. Journal of Allergy and Clinical Immunology 127(3):668-76.e1\u20132","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"5","key":"9104_CR4","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/j.1442-200X.2010.03166.x","volume":"52","author":"Y Hu","year":"2010","unstructured":"Hu Y, Chen J, Li H (2010) Comparison of food allergy prevalence among Chinese infants in Chongqing, 2009 versus 1999. Pediatr Int 52(5):820\u2013824","journal-title":"Pediatr Int"},{"key":"9104_CR5","doi-asserted-by":"crossref","unstructured":"Peters RL, Koplin JJ, Gurrin LC, Dharmage SC, Wake M, Ponsonby AL et al (2017) The prevalence of food allergy and other allergic diseases in early childhood in a population-based study: HealthNuts age 4-year follow-up. J Allergy Clin Immunol 140(1):145\u201353.e8","DOI":"10.1016\/j.jaci.2017.02.019"},{"issue":"8","key":"9104_CR6","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1111\/all.12630","volume":"70","author":"AA Schoemaker","year":"2015","unstructured":"Schoemaker AA, Sprikkelman AB, Grimshaw KE, Roberts G, Grabenhenrich L, Rosenfeld L et al (2015) Incidence and natural history of challenge-proven cow\u2019s milk allergy in European children\u2014EuroPrevall birth cohort. Allergy 70(8):963\u2013972","journal-title":"Allergy"},{"issue":"7","key":"9104_CR7","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1111\/j.1399-3038.2012.01275.x","volume":"23","author":"S Tsabouri","year":"2012","unstructured":"Tsabouri S, Triga M, Makris M, Kalogeromitros D, Church MK, Priftis KN (2012) Fish and shellfish allergy in children: review of a persistent food allergy. Pediatr Allergy Immunol 23(7):608\u2013615","journal-title":"Pediatr Allergy Immunol"},{"issue":"3","key":"9104_CR8","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.jaci.2004.11.053","volume":"115","author":"S Holgate","year":"2005","unstructured":"Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C (2005) The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 115(3):459\u2013465","journal-title":"J Allergy Clin Immunol"},{"key":"9104_CR9","doi-asserted-by":"publisher","first-page":"1617153","DOI":"10.3389\/fimmu.2025.1617153","volume":"16","author":"MD Kulis","year":"2025","unstructured":"Kulis MD, Humphrey JR, Krempski JW, Kim EH, Smeekens JM (2025) Anti-IgE therapy versus allergen-specific immunotherapy for food allergy: weighing the pros and cons. Front Immunol 16:1617153","journal-title":"Front Immunol"},{"issue":"10","key":"9104_CR10","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1056\/NEJMoa2312382","volume":"390","author":"RA Wood","year":"2024","unstructured":"Wood RA, Togias A, Sicherer SH, Shreffler WG, Kim EH, Jones SM et al (2024) Omalizumab for the treatment of multiple food allergies. N Engl J Med 390(10):889\u2013899","journal-title":"N Engl J Med"},{"issue":"3","key":"9104_CR11","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1056\/NEJMoa1200435","volume":"367","author":"AW Burks","year":"2012","unstructured":"Burks AW, Jones SM, Wood RA, Fleischer DM, Sicherer SH, Lindblad RW et al (2012) Oral immunotherapy for treatment of egg allergy in children. N Engl J Med 367(3):233\u2013243","journal-title":"N Engl J Med"},{"issue":"8","key":"9104_CR12","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1111\/all.13124","volume":"72","author":"U Nurmatov","year":"2017","unstructured":"Nurmatov U, Dhami S, Arasi S, Pajno GB, Fernandez-Rivas M, Muraro A et al (2017) Allergen immunotherapy for IgE-mediated food allergy: a systematic review and meta-analysis. Allergy 72(8):1133\u20131147","journal-title":"Allergy"},{"issue":"4","key":"9104_CR13","first-page":"CD010638","volume":"4","author":"O Romantsik","year":"2018","unstructured":"Romantsik O, Tosca MA, Zappettini S, Calevo MG (2018) Oral and sublingual immunotherapy for egg allergy. Cochrane Database Syst Rev 4(4):CD010638","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"9104_CR14","doi-asserted-by":"publisher","first-page":"e111649","DOI":"10.1371\/journal.pone.0111649","volume":"9","author":"CY Wai","year":"2014","unstructured":"Wai CY, Leung NY, Ho MH, Gershwin LJ, Shu SA, Leung PS et al (2014) Immunization with hypoallergens of shrimp allergen tropomyosin inhibits shrimp tropomyosin-specific IgE reactivity. PLoS ONE 9(11):e111649","journal-title":"PLoS ONE"},{"issue":"10","key":"9104_CR15","doi-asserted-by":"publisher","first-page":"6290","DOI":"10.4049\/jimmunol.178.10.6290","volume":"178","author":"I Swoboda","year":"2007","unstructured":"Swoboda I, Bugajska-Schretter A, Linhart B, Verdino P, Keller W, Schulmeister U et al (2007) A recombinant hypoallergenic parvalbumin mutant for immunotherapy of IgE-mediated fish allergy. J Immunol 178(10):6290\u20136296","journal-title":"J Immunol"},{"issue":"1","key":"9104_CR16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000371657","volume":"166","author":"L Zuidmeer-Jongejan","year":"2015","unstructured":"Zuidmeer-Jongejan L, Huber H, Swoboda I, Rigby N, Versteeg SA, Jensen BM et al (2015) Development of a hypoallergenic recombinant parvalbumin for first-in-man subcutaneous immunotherapy of fish allergy. Int Arch Allergy Immunol 166(1):41\u201351","journal-title":"Int Arch Allergy Immunol"},{"key":"9104_CR17","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.foodchem.2019.03.019","volume":"288","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, Xiao H, Zhou P (2019) Allergenicity suppression of tropomyosin from Exopalaemon modestus by glycation with saccharides of different molecular sizes. Food Chem 288:268\u2013275","journal-title":"Food Chem"},{"issue":"6","key":"9104_CR18","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1039\/D0FO03039B","volume":"12","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Li X-M, Li Z, Lin H (2021) Investigation of glycated shrimp tropomyosin as a hypoallergen for potential immunotherapy. Food Funct 12(6):2750\u20132759","journal-title":"Food Funct"},{"key":"9104_CR19","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.molimm.2017.02.005","volume":"85","author":"J Anzengruber","year":"2017","unstructured":"Anzengruber J, Bublin M, Bonisch E, Janesch B, Tscheppe A, Braun ML et al (2017) Lactobacillus buchneri S-layer as carrier for an Ara h 2-derived peptide for peanut allergen-specific immunotherapy. Mol Immunol 85:81\u201388","journal-title":"Mol Immunol"},{"issue":"3","key":"9104_CR20","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/cea.12684","volume":"46","author":"CY Wai","year":"2016","unstructured":"Wai CY, Leung NY, Leung PS, Chu KH (2016) T cell epitope immunotherapy ameliorates allergic responses in a murine model of shrimp allergy. Clin Exp Allergy 46(3):491\u2013503","journal-title":"Clin Exp Allergy"},{"key":"9104_CR21","doi-asserted-by":"publisher","first-page":"128926","DOI":"10.1016\/j.foodchem.2020.128926","volume":"346","author":"AM Candreva","year":"2021","unstructured":"Candreva AM, Smaldini PL, Cauerhff A, Petruccelli S, Docena GH (2021) A novel approach to ameliorate experimental milk allergy based on the oral administration of a short soy cross-reactive peptide. Food Chem 346:128926","journal-title":"Food Chem"},{"issue":"1","key":"9104_CR22","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1038\/s41598-019-40114-7","volume":"9","author":"MJ Rodriguez","year":"2019","unstructured":"Rodriguez MJ, Ramos-Soriano J, Perkins JR, Mascaraque A, Torres MJ, Gomez F et al (2019) Glycosylated nanostructures in sublingual immunotherapy induce long-lasting tolerance in LTP allergy mouse model. Sci Rep 9(1):4043","journal-title":"Sci Rep"},{"key":"9104_CR23","doi-asserted-by":"publisher","first-page":"1094172","DOI":"10.3389\/fimmu.2022.1094172","volume":"13","author":"R Nunez","year":"2022","unstructured":"Nunez R, Rodriguez MJ, Lebron-Martin C, Martin-Astorga MDC, Palomares F, Ramos-Soriano J et al (2022) Methylation changes induced by glycodendropeptide immunotherapy and associated with tolerance in mice. Front Immunol 13:1094172","journal-title":"Front Immunol"},{"key":"9104_CR24","doi-asserted-by":"publisher","first-page":"1165852","DOI":"10.3389\/fimmu.2023.1165852","volume":"14","author":"R Nunez","year":"2023","unstructured":"Nunez R, Rodriguez MJ, Lebron-Martin C, Martin-Astorga MDC, Ramos-Soriano J, Rojo J et al (2023) A synthetic glycodendropeptide induces methylation changes on regulatory T cells linked to tolerant responses in anaphylactic mice. Front Immunol 14:1165852","journal-title":"Front Immunol"},{"issue":"4","key":"9104_CR25","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1080\/09168451.2019.1699395","volume":"84","author":"J Hong","year":"2020","unstructured":"Hong J, Gao Q, Xiao X, Cao H, Yuan R, Liu Z et al (2020) T cell epitope of arginine kinase with CpG co-encapsulated nanoparticles attenuates shrimp allergen-induced Th2-bias food allergy. Biosci Biotechnol Biochem 84(4):804\u2013814","journal-title":"Biosci Biotechnol Biochem"},{"key":"9104_CR26","doi-asserted-by":"publisher","first-page":"969337","DOI":"10.3389\/falgy.2022.969337","volume":"3","author":"JM Smeekens","year":"2022","unstructured":"Smeekens JM, Kesselring JR, Frizzell H, Bagley KC, Kulis MD (2022) Induction of food-specific IgG by gene gun-delivered DNA vaccines. Front Allergy 3:969337","journal-title":"Front Allergy"},{"key":"9104_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20184656","author":"CYY Wai","year":"2019","unstructured":"Wai CYY, Leung NYH, Leung PSC, Chu KH (2019) Modulating shrimp tropomyosin-mediated allergy: hypoallergen DNA vaccines induce regulatory T cells to reduce hypersensitivity in mouse model. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms20184656","journal-title":"Int J Mol Sci"},{"issue":"Pt A","key":"9104_CR28","doi-asserted-by":"publisher","first-page":"109394","DOI":"10.1016\/j.intimp.2022.109394","volume":"113","author":"K Kubo","year":"2022","unstructured":"Kubo K, Takeda S, Uchida M, Maeda M, Endo N, Sugahara S et al (2022) Lit-LAMP-DNA vaccine for shrimp allergy prevents anaphylactic symptoms in a murine model. Int Immunopharmacol 113(Pt A):109394","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"9104_CR29","doi-asserted-by":"publisher","first-page":"AB167","DOI":"10.1016\/j.jaci.2014.12.1482","volume":"135","author":"X-M Li","year":"2015","unstructured":"Li X-M, Song Y, Su Y, Heiland T, Sampson HA (2015) Immunization with ARA h1,2,3-lamp-vax peanut vaccine blocked IgE mediated-anaphylaxis in a peanut allergic murine model. J Allergy Clin Immunol 135(2):AB167","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"9104_CR30","doi-asserted-by":"publisher","first-page":"4942","DOI":"10.1021\/acsnano.2c12420","volume":"17","author":"X Xu","year":"2023","unstructured":"Xu X, Wang X, Liao YP, Luo L, Xia T, Nel AE (2023) Use of a liver-targeting immune-tolerogenic mRNA lipid nanoparticle platform to treat peanut-induced anaphylaxis by single- and multiple-epitope nucleotide sequence delivery. ACS Nano 17(5):4942\u20134957","journal-title":"ACS Nano"},{"key":"9104_CR31","doi-asserted-by":"crossref","unstructured":"Larsen JE, Lund O, Nielsen M (2006) Improved method for predicting linear B-cell epitopes. Immunome Res 2(1):2","DOI":"10.1186\/1745-7580-2-2"},{"issue":"3","key":"9104_CR32","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1128\/jvi.55.3.836-839.1985","volume":"55","author":"EA Emini","year":"1985","unstructured":"Emini EA, Hughes JV, Perlow DS, Boger J (1985) Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide. J Virol 55(3):836\u2013839","journal-title":"J Virol"},{"issue":"1\u20132","key":"9104_CR33","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/0014-5793(90)80535-Q","volume":"276","author":"AS Kolaskar","year":"1990","unstructured":"Kolaskar AS, Tongaonkar PC (1990) A semi-empirical method for prediction of antigenic determinants on protein antigens. FEBS Lett 276(1\u20132):172\u2013174","journal-title":"FEBS Lett"},{"key":"9104_CR34","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.molimm.2020.12.033","volume":"131","author":"MF Sharp","year":"2021","unstructured":"Sharp MF, Taki AC, Ruethers T, Stephen JN, Daly NL, Lopata AL et al (2021) IgE and IgG(4) epitopes revealed on the major fish allergen Lat c 1. Mol Immunol 131:155\u2013163","journal-title":"Mol Immunol"},{"issue":"3","key":"9104_CR35","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1159\/000519618","volume":"183","author":"M Suprun","year":"2022","unstructured":"Suprun M, Sicherer SH, Wood RA, Jones SM, Leung DYM, Burks AW et al (2022) Mapping sequential IgE-binding epitopes on major and minor egg allergens. Int Arch Allergy Immunol 183(3):249\u2013261","journal-title":"Int Arch Allergy Immunol"},{"key":"9104_CR36","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.foodchem.2018.09.068","volume":"274","author":"L Fu","year":"2019","unstructured":"Fu L, Wang C, Wang J, Ni S, Wang Y (2019) Maillard reaction with ribose, galacto-oligosaccharide, or chitosan-oligosaccharide reduces allergenicity of shrimp tropomyosin by inducing conformational changes. Food Chem 274:789\u2013795","journal-title":"Food Chem"},{"issue":"10","key":"9104_CR37","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1021\/bm300998c","volume":"13","author":"R Ribeiro-Viana","year":"2012","unstructured":"Ribeiro-Viana R, Garcia-Vallejo JJ, Collado D, Perez-Inestrosa E, Bloem K, van Kooyk Y et al (2012) BODIPY-labeled DC-SIGN-targeting glycodendrons efficiently internalize and route to lysosomes in human dendritic cells. Biomacromol 13(10):3209\u20133219","journal-title":"Biomacromol"},{"key":"9104_CR38","doi-asserted-by":"crossref","unstructured":"Renand A, Newbrough S, Wambre E, DeLong JH, Robinson D, Kwok WW (2024) Arginine kinase Pen m 2 as an important shrimp allergen recognized by th2 cells. J Allergy Clin Immunol 134(6):1456\u20139.e7","DOI":"10.1016\/j.jaci.2014.07.048"},{"key":"9104_CR39","doi-asserted-by":"crossref","unstructured":"Ferslew BC, Smulders R, Zhu T, Blauwet MB, Kusawake T, Spence A et al (2024) Safety and Immunopharmacology of ASP0892 in adults or adolescents with peanut allergy: two randomized trials allergy. Allergy 79(2):456\u201370","DOI":"10.1111\/all.15931"},{"issue":"27","key":"9104_CR40","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S et al (2020) Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 383(27):2603\u20132615","journal-title":"N Engl J Med"},{"issue":"6525","key":"9104_CR41","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1126\/science.aay3638","volume":"371","author":"C Krienke","year":"2021","unstructured":"Krienke C, Kolb L, Diken E, Streuber M, Kirchhoff S, Bukur T et al (2021) A noninflammatory mrna vaccine for treatment of experimental autoimmune encephalomyelitis. Science 371(6525):145\u2013153","journal-title":"Science"},{"issue":"5","key":"9104_CR42","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/j.0818-9641.2004.01272.x","volume":"82","author":"N Petrovsky","year":"2004","unstructured":"Petrovsky N, Aguilar JC (2004) Vaccine adjuvants: current state and future trends. Immunol Cell Biol 82(5):488\u2013496","journal-title":"Immunol Cell Biol"},{"issue":"3","key":"9104_CR43","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.jaci.2023.10.013","volume":"153","author":"LM Rad","year":"2024","unstructured":"Rad LM, Arellano G, Podojil JR, O\u2019Konek JJ, Shea LD, Miller SD (2024) Engineering nanoparticle therapeutics for food allergy. J Allergy Clin Immunol 153(3):549\u2013559","journal-title":"J Allergy Clin Immunol"},{"key":"9104_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1348305","author":"Y-J Lin","year":"2024","unstructured":"Lin Y-J, Zimmermann J, Sch\u00fclke S (2024) Novel adjuvants in allergen-specific immunotherapy: where do we stand? Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2024.1348305","journal-title":"Front Immunol"},{"key":"9104_CR45","doi-asserted-by":"crossref","unstructured":"Orgel KA, Duan S, Wright BL, Maleki SJ, Wolf JC, Vickery BP et al (2017) Exploiting CD22 on antigen-specific b cells to prevent allergy to the major peanut allergen Ara h 2. Allergy Clin Immunol 139(1):366\u20139 e2","DOI":"10.1016\/j.jaci.2016.06.053"},{"issue":"6","key":"9104_CR46","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.jaci.2022.06.022","volume":"150","author":"LC Hardy","year":"2022","unstructured":"Hardy LC, Smeekens JM, Raghuwanshi D, Sarkar S, Daskhan GC, Rogers S et al (2022) Targeting CD22 on memory b cells to induce tolerance to peanut allergens. J Allergy Clin Immunol 150(6):1476-1485.e4","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"9104_CR47","first-page":"2290","volume":"206","author":"S Duan","year":"2021","unstructured":"Duan S, Arlian BM, Nycholat CM, Wei Y, Tateno H, Smith SA et al (2021) Nanoparticles displaying allergen and siglec-8 ligands suppress IgE-FcepsilonRI-mediated anaphylaxis and desensitize mast cells to subsequent antigen challenge. J Immunol Res 206(10):2290\u20132300","journal-title":"J Immunol Res"},{"issue":"3","key":"9104_CR48","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.pharmthera.2012.06.005","volume":"135","author":"T Kiwamoto","year":"2012","unstructured":"Kiwamoto T, Kawasaki N, Paulson JC, Bochner BS (2012) Siglec-8 as a druggable target to treat eosinophil and mast cell-associated conditions. Pharmacol Ther 135(3):327\u2013336","journal-title":"Pharmacol Ther"},{"key":"9104_CR49","doi-asserted-by":"crossref","unstructured":"Srivastava KD, Siefert A, Fahmy TM, Caplan MJ, Li XM, Sampson HA (2016) Investigation of peanut oral immunotherapy with CpG\/peanut nanoparticles in a murine model of peanut allergy. J Allergy Clin Immunol. 2016;138(2):536\u201343 e4.","DOI":"10.1016\/j.jaci.2016.01.047"},{"key":"9104_CR50","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ejphar.2017.10.051","volume":"818","author":"AI Kostadinova","year":"2018","unstructured":"Kostadinova AI, Middelburg J, Ciulla M, Garssen J, Hennink WE, Knippels LMJ et al (2018) PLGA nanoparticles loaded with beta-lactoglobulin-derived peptides modulate mucosal immunity and may facilitate cow\u2019s milk allergy prevention. Eur J Pharmacol 818:211\u2013220","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"9104_CR51","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/cea.13967","volume":"52","author":"M Liu","year":"2022","unstructured":"Liu M, Thijssen S, van Nostrum CF, Hennink WE, Garssen J, Willemsen LEM (2022) Inhibition of cow\u2019s milk allergy development in mice by oral delivery of beta-lactoglobulin-derived peptides loaded in PLGA nanoparticles is associated with systemic whey-specific immune silencing. Clin Exp Allergy 52(1):137\u2013148","journal-title":"Clin Exp Allergy"},{"key":"9104_CR52","doi-asserted-by":"publisher","first-page":"1053107","DOI":"10.3389\/fimmu.2022.1053107","volume":"13","author":"M Liu","year":"2022","unstructured":"Liu M, Thijssen S, Hennink WE, Garssen J, van Nostrum CF, Willemsen LEM (2022) Oral pretreatment with beta-lactoglobulin derived peptide and CpG co-encapsulated in PLGA nanoparticles prior to sensitizations attenuates cow\u2019s milk allergy development in mice. Front Immunol 13:1053107","journal-title":"Front Immunol"},{"key":"9104_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/falgy.2022.829605","volume":"3","author":"KR Hughes","year":"2022","unstructured":"Hughes KR, Saunders MN, Landers JJ, Janczak KW, Turkistani H, Rad LM et al (2022) Masked delivery of allergen in nanoparticles safely attenuates anaphylactic response in murine models of peanut allergy. Front Allergy 3:829605","journal-title":"Front Allergy"},{"key":"9104_CR54","doi-asserted-by":"crossref","unstructured":"Saunders MN, Rad LM, Williams LA, Landers JJ, Urie RR, Hocevar SE, Quiros M, Chiang MY, Angadi AR, Janczak KW, Bealer EJ (2024) Allergen-encapsulating nanoparticles reprogram pathogenic allergen-specific Th2 cells to suppress food allergy. Adv Healthc Mater 14(5):2400237","DOI":"10.1002\/adhm.202400237"},{"key":"9104_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/falgy.2024.1437523","volume":"5","author":"MN Saunders","year":"2024","unstructured":"Saunders MN, Rival CM, Mandal M, Cramton K, Rad LM, Janczak KW et al (2024) Immunotherapy with biodegradable nanoparticles encapsulating the oligosaccharide galactose-alpha-1,3-galactose enhances immune tolerance against alpha-gal sensitization in a murine model of alpha-gal syndrome. Front Allergy 5:1437523","journal-title":"Front Allergy"},{"key":"9104_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/molecules29174123","author":"R Sakurai","year":"2024","unstructured":"Sakurai R, Iwata H, Gotoh M, Ogino H, Takeuchi I, Makino K et al (2024) Application of PLGA-PEG-PLGA nanoparticles to percutaneous immunotherapy for food allergy. Molecules. https:\/\/doi.org\/10.3390\/molecules29174123","journal-title":"Molecules"},{"issue":"8","key":"9104_CR57","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1128\/CVI.00359-14","volume":"21","author":"SRJ De","year":"2014","unstructured":"De SRJ, Irache JM, Camacho AI, Gastaminza G, Sanz ML, Ferrer M et al (2014) Immunogenicity of peanut proteins containing poly(anhydride) nanoparticles. Clin Vaccine Immunol 21(8):1106\u20131112","journal-title":"Clin Vaccine Immunol"},{"issue":"15","key":"9104_CR58","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.2217\/imt-2017-0111","volume":"9","author":"C Gamazo","year":"2017","unstructured":"Gamazo C, Garcia-Azpiroz M, Souza Reboucas J, Gastaminza G, Ferrer M, Irache JM (2017) Oral immunotherapy using polymeric nanoparticles loaded with peanut proteins in a murine model of fatal anaphylaxis. Immunotherapy 9(15):1205\u20131217","journal-title":"Immunotherapy"},{"key":"9104_CR59","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ejpb.2018.02.011","volume":"127","author":"MA Pereira","year":"2018","unstructured":"Pereira MA, Reboucas JS, Ferraz-Carvalho RS, de Redin IL, Guerra PV, Gamazo C et al (2018) Poly(anhydride) nanoparticles containing cashew nut proteins can induce a strong Th1 and Treg immune response after oral administration. Eur J Pharm Biopharm 127:51\u201360","journal-title":"Eur J Pharm Biopharm"},{"issue":"9","key":"9104_CR60","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1089\/vim.2014.0059","volume":"27","author":"K Manzano-Szalai","year":"2014","unstructured":"Manzano-Szalai K, Thell K, Willensdorfer A, Weghofer M, Pfanzagl B, Singer J et al (2014) Adeno-associated virus-like particles as new carriers for B-cell vaccines: testing immunogenicity and safety in BALB\/c mice. Viral Immunol 27(9):438\u2013448","journal-title":"Viral Immunol"},{"key":"9104_CR61","unstructured":"Aguilar Conde A (2020) Inmunoterapia Basada en NoVLPs como Tratamiento Potencial para la Alergia al Melocot\u00f3n.\u00a0Trabajo Fin de Grado \/ Proyecto Fin de Carrera, E.T.S. de Ingenier\u00eda Agron\u00f3mica, Alimentaria y de Biosistemas (UPM), Madrid"},{"key":"9104_CR62","doi-asserted-by":"publisher","first-page":"986823","DOI":"10.3389\/fimmu.2022.986823","volume":"13","author":"D Pazos-Castro","year":"2022","unstructured":"Pazos-Castro D, Margain C, Gonzalez-Klein Z, Amores-Borge M, Yuste-Calvo C, Garrido-Arandia M et al (2022) Suitability of potyviral recombinant virus-like particles bearing a complete food allergen for immunotherapy vaccines. Front Immunol 13:986823","journal-title":"Front Immunol"},{"key":"9104_CR63","doi-asserted-by":"crossref","unstructured":"Storni F, Zeltins A, Balke I, Heath MD, Kramer MF, Skinner MA et al (2020) Vaccine against peanut allergy based on engineered virus-like particles displaying single major peanut allergens. J Allergy Clin Immunol 145(4):1240\u201353 e3","DOI":"10.1016\/j.jaci.2019.12.007"},{"issue":"7","key":"9104_CR64","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1111\/all.15704","volume":"78","author":"JM Sobczak","year":"2023","unstructured":"Sobczak JM, Krenger PS, Storni F, Mohsen MO, Balke I, Resevica G et al (2023) The next generation virus-like particle platform for the treatment of peanut allergy. Allergy 78(7):1980\u20131996","journal-title":"Allergy"},{"issue":"5","key":"9104_CR65","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/cea.14294","volume":"53","author":"C Castenmiller","year":"2023","unstructured":"Castenmiller C, Stigler M, Kirpas ME, Versteeg S, Akkerdaas JH, Pena-Castellanos G et al (2023) Plant-based enveloped Ara h 2 bioparticles display exceptional hypo-allergenicity. Clin Exp Allergy 53(5):577\u2013581","journal-title":"Clin Exp Allergy"},{"issue":"11","key":"9104_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2023.100839","volume":"16","author":"C Castenmiller","year":"2023","unstructured":"Castenmiller C, Nagy NA, Kroon PZ, Auger L, Desgagnes R, Martel C et al (2023) A novel peanut allergy immunotherapy: plant-based enveloped Ara h 2 bioparticles activate dendritic cells and polarize T cell responses to Th1. World Allergy Organ J 16(11):100839","journal-title":"World Allergy Organ J"},{"issue":"3 Pt A","key":"9104_CR67","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.ejpb.2013.03.003","volume":"85","author":"I Pali-Scholl","year":"2013","unstructured":"Pali-Scholl I, Szollosi H, Starkl P, Scheicher B, Stremnitzer C, Hofmeister A et al (2013) Protamine nanoparticles with CpG-oligodeoxynucleotide prevent an allergen-induced Th2-response in BALB\/c mice. Eur J Pharm Biopharm 85(3 Pt A):656\u2013664","journal-title":"Eur J Pharm Biopharm"},{"issue":"1\u20133","key":"9104_CR68","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.molimm.2010.07.006","volume":"48","author":"S Schulke","year":"2010","unstructured":"Schulke S, Waibler Z, Mende MS, Zoccatelli G, Vieths S, Toda M et al (2010) Fusion protein of TLR5-ligand and allergen potentiates activation and IL-10 secretion in murine myeloid dendritic cells. Mol Immunol 48(1\u20133):341\u2013350","journal-title":"Mol Immunol"},{"issue":"6","key":"9104_CR69","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.jaci.2011.07.036","volume":"128","author":"S Schulke","year":"2011","unstructured":"Schulke S, Burggraf M, Waibler Z, Wangorsch A, Wolfheimer S, Kalinke U et al (2011) A fusion protein of flagellin and ovalbumin suppresses the TH2 response and prevents murine intestinal allergy. J Allergy Clin Immunol 128(6):1340-1348.e12","journal-title":"J Allergy Clin Immunol"},{"key":"9104_CR70","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/3605977","volume":"2022","author":"HT Zeng","year":"2022","unstructured":"Zeng HT, Liu Y, Zhao M, Liu JQ, Jin QR, Liu ZQ et al (2022) Modulating oxidative stress in B cells promotes immunotherapy in food allergy. Oxid Med Cell Longev 2022:3605977","journal-title":"Oxid Med Cell Longev"},{"issue":"2","key":"9104_CR71","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.jaci.2019.11.022","volume":"145","author":"Y Yu","year":"2020","unstructured":"Yu Y, Kiran Kumar MN, Wu MX (2020) Delivery of allergen powder for safe and effective epicutaneous immunotherapy. J Allergy Clin Immunol 145(2):597\u2013609","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"9104_CR72","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1016\/j.jaci.2018.01.042","volume":"141","author":"JJ O'Konek","year":"2018","unstructured":"O\u2019Konek JJ, Landers JJ, Janczak KW, Goel RR, Mondrusov AM, Wong PT et al (2018) Nanoemulsion adjuvant-driven redirection of T(H)2 immunity inhibits allergic reactions in murine models of peanut allergy. J Allergy Clin Immunol 141(6):2121\u20132131","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"9104_CR73","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/all.13977","volume":"75","author":"JJ O'Konek","year":"2020","unstructured":"O\u2019Konek JJ, Baker JR Jr (2020) Treatment of allergic disease with nanoemulsion adjuvant vaccines. Allergy 75(1):246\u2013249","journal-title":"Allergy"},{"issue":"4","key":"9104_CR74","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1111\/all.14064","volume":"75","author":"JJ O'Konek","year":"2020","unstructured":"O\u2019Konek JJ, Landers JJ, Janczak KW, Lindsey HK, Mondrusov AM, Totten TD et al (2020) Intranasal nanoemulsion vaccine confers long-lasting immunomodulation and sustained unresponsiveness in a murine model of milk allergy. Allergy 75(4):872\u2013881","journal-title":"Allergy"},{"key":"9104_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.599296","volume":"12","author":"M Farazuddin","year":"2021","unstructured":"Farazuddin M, Landers JJ, Janczak KW, Lindsey HK, Finkelman FD, Baker JR Jr et al (2021) Mucosal nanoemulsion allergy vaccine suppresses alarmin expression and induces bystander suppression of reactivity to multiple food allergens. Front Immunol 12:599296","journal-title":"Front Immunol"},{"issue":"6","key":"9104_CR76","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/cea.13862","volume":"51","author":"P Sorensen","year":"2021","unstructured":"Sorensen P, Turanek-Knotigova P, Masek J, Kotoucek J, Hubatka F, Maskova E et al (2021) Short-course sublingual immunotherapy by mucoadhesive patch and tolerogenic particle enhanced allergen presentation. Clin Exp Allergy 51(6):853\u2013857","journal-title":"Clin Exp Allergy"},{"issue":"3","key":"9104_CR77","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1111\/all.15607","volume":"78","author":"F Palomares","year":"2023","unstructured":"Palomares F, Mayorga C, Leenhouts K, Perez-Sanchez N, Gomez F, Torres MJ et al (2023) Lactococcus lactis-derived microparticles mixed with allergen shift immune responses towards a regulatory profile in tree-nut allergic patients. Allergy 78(3):851\u2013855","journal-title":"Allergy"},{"key":"9104_CR78","doi-asserted-by":"publisher","first-page":"474605","DOI":"10.1155\/2012\/474605","volume":"2012","author":"J De Souza Reboucas","year":"2012","unstructured":"De Souza Reboucas J, Esparza I, Ferrer M, Sanz ML, Irache JM, Gamazo C (2012) Nanoparticulate adjuvants and delivery systems for allergen immunotherapy. J Biomed Biotechnol 2012:474605","journal-title":"J Biomed Biotechnol"},{"issue":"10","key":"9104_CR79","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1111\/all.13199","volume":"72","author":"H Pohlit","year":"2017","unstructured":"Pohlit H, Bellinghausen I, Frey H, Saloga J (2017) Recent advances in the use of nanoparticles for allergen-specific immunotherapy. Allergy 72(10):1461\u20131474","journal-title":"Allergy"},{"issue":"16","key":"9104_CR80","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.3390\/molecules25163731","volume":"25","author":"A Zielinska","year":"2020","unstructured":"Zielinska A, Carreiro F, Oliveira AM, Neves A, Pires B, Venkatesh DN et al (2020) Polymeric nanoparticles: production, characterization, toxicology and ecotoxicology. Molecules 25(16):3731","journal-title":"Molecules"},{"issue":"1","key":"9104_CR81","doi-asserted-by":"publisher","first-page":"23","DOI":"10.4168\/aair.2021.13.1.23","volume":"13","author":"P Pechsrichuang","year":"2021","unstructured":"Pechsrichuang P, Namwongnao S, Jacquet A (2021) Bioengineering of virus-like particles for the prevention or treatment of allergic diseases. Allergy Asthma Immunol Res 13(1):23\u201341","journal-title":"Allergy Asthma Immunol Res"},{"issue":"12","key":"9104_CR82","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11882-018-0827-1","volume":"18","author":"M Anzaghe","year":"2018","unstructured":"Anzaghe M, Schulke S, Scheurer S (2018) Virus-like particles as carrier systems to enhance immunomodulation in allergen immunotherapy. Curr Allergy Asthma Rep 18(12):71","journal-title":"Curr Allergy Asthma Rep"},{"issue":"8","key":"9104_CR83","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1111\/all.16090","volume":"79","author":"Z Gharailoo","year":"2024","unstructured":"Gharailoo Z, Plattner K, Augusto G, Engeroff P, Vogel M, Bachmann MF (2024) Generation of a virus-like particles based vaccine against IgE. Allergy 79(8):2207\u20132221","journal-title":"Allergy"},{"issue":"5","key":"9104_CR84","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1016\/j.jaip.2020.12.008","volume":"9","author":"E Jensen-Jarolim","year":"2021","unstructured":"Jensen-Jarolim E, Roth-Walter F, Jordakieva G, Pali-Scholl I (2021) Allergens and adjuvants in allergen immunotherapy for immune activation, tolerance, and resilience. J Allergy Clin Immunol Pract 9(5):1780\u20131789","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"12","key":"9104_CR85","doi-asserted-by":"publisher","first-page":"e0242867","DOI":"10.1371\/journal.pone.0242867","volume":"15","author":"V Gomord","year":"2020","unstructured":"Gomord V, Stordeur V, Fitchette AC, Fixman ED, Tropper G, Garnier L et al (2020) Design, production and immunomodulatory potency of a novel allergen bioparticle. PLoS ONE 15(12):e0242867","journal-title":"PLoS ONE"},{"issue":"10","key":"9104_CR86","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1111\/all.15464","volume":"77","author":"S Busold","year":"2022","unstructured":"Busold S, Aglas L, Menage C, Auger L, Desgagnes R, Faye L et al (2022) Fel d 1 surface expression on plant-made ebioparticles combines potent immune activation and hypoallergenicity. Allergy 77(10):3124\u20133126","journal-title":"Allergy"},{"key":"9104_CR87","doi-asserted-by":"publisher","DOI":"10.3389\/falgy.2024.1473352","volume":"5","author":"M Mennini","year":"2024","unstructured":"Mennini M, Piccirillo M, Furio S, Valitutti F, Ferretti A, Strisciuglio C et al (2024) Probiotics and other adjuvants in allergen-specific immunotherapy for food allergy: a comprehensive review. Front Allergy 5:1473352","journal-title":"Front Allergy"},{"issue":"1","key":"9104_CR88","first-page":"4857869","volume":"2016","author":"Y Su","year":"2016","unstructured":"Su Y, Connolly M, Marketon A, Heiland T (2016) CryJ-LAMP DNA vaccines for Japanese red cedar allergy induce robust Th1-type immune responses in murine model. J Immunol Res 2016(1):4857869","journal-title":"J Immunol Res"},{"issue":"12","key":"9104_CR89","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1080\/21645515.2017.1329070","volume":"13","author":"Y Su","year":"2017","unstructured":"Su Y, Romeu-Bonilla E, Anagnostou A, Fitz-Patrick D, Hearl W, Heiland T (2017) Safety and long-term immunological effects of CryJ2-LAMP plasmid vaccine in Japanese Red Cedar atopic subjects: a phase I study. Hum Vaccin Immunother 13(12):2804\u20132813","journal-title":"Hum Vaccin Immunother"},{"key":"9104_CR90","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ejps.2015.04.009","volume":"75","author":"B Scheicher","year":"2015","unstructured":"Scheicher B, Schachner-Nedherer AL, Zimmer A (2015) Protamine-oligonucleotide nanoparticles: recent advances in drug delivery and drug targeting. Eur J Pharm Sci 75:54\u201359","journal-title":"Eur J Pharm Sci"},{"issue":"6","key":"9104_CR91","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/s41587-022-01294-2","volume":"40","author":"AJ Barbier","year":"2022","unstructured":"Barbier AJ, Jiang AY, Zhang P, Wooster R, Anderson DG (2022) The clinical progress of mRNA vaccines and immunotherapies. Nat Biotechnol 40(6):840\u2013854","journal-title":"Nat Biotechnol"},{"issue":"10","key":"9104_CR92","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1007\/s11095-007-9318-0","volume":"24","author":"JM Martinez Gomez","year":"2007","unstructured":"Martinez Gomez JM, Fischer S, Csaba N, Kundig TM, Merkle HP, Gander B et al (2007) A protective allergy vaccine based on CpG- and protamine-containing PLGA microparticles. Pharm Res 24(10):1927\u20131935","journal-title":"Pharm Res"},{"issue":"4","key":"9104_CR93","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/nrd3203","volume":"9","author":"EJ Hennessy","year":"2010","unstructured":"Hennessy EJ, Parker AE, O\u2019Neill LA (2010) Targeting toll-like receptors: emerging therapeutics? Nat Rev Drug Discovery 9(4):293\u2013307","journal-title":"Nat Rev Drug Discovery"},{"issue":"11","key":"9104_CR94","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.3390\/vaccines12111212","volume":"12","author":"S Pang","year":"2024","unstructured":"Pang S, Liu M, Wang L, Shao M, Zhu G, Duan Q (2024) Differential adjuvant activity by flagellins from Escherichia coli, Salmonella enterica serotype typhimurium, and Pseudomonas aeruginosa. Vaccines 12(11):1212","journal-title":"Vaccines"},{"issue":"32","key":"9104_CR95","doi-asserted-by":"publisher","first-page":"5145","DOI":"10.1016\/j.vaccine.2011.05.041","volume":"29","author":"CB Turley","year":"2011","unstructured":"Turley CB, Rupp RE, Johnson C, Taylor DN, Wolfson J, Tussey L et al (2011) Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine 29(32):5145\u20135152","journal-title":"Vaccine"},{"issue":"1","key":"9104_CR96","doi-asserted-by":"publisher","first-page":"ofw015","DOI":"10.1093\/ofid\/ofw015","volume":"3","author":"L Tussey","year":"2016","unstructured":"Tussey L, Strout C, Davis M, Johnson C, Lucksinger G, Umlauf S et al (2016) Phase 1 safety and immunogenicity study of a quadrivalent seasonal flu vaccine comprising recombinant hemagglutinin-flagellin fusion proteins. Open Forum Infect Dis 3(1):ofw015","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"9104_CR97","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s40629-018-0074-y","volume":"27","author":"L Klimek","year":"2018","unstructured":"Klimek L, Kundig T, Kramer MF, Guethoff S, Jensen-Jarolim E, Schmidt-Weber CB et al (2018) Virus-like particles (VLPs) in prophylaxis and immunotherapy of allergic diseases. Allergo J Int 27(8):245\u2013255","journal-title":"Allergo J Int"},{"key":"9104_CR98","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/978-1-0716-0872-2_4","volume":"2197","author":"N Kayraklioglu","year":"2021","unstructured":"Kayraklioglu N, Horuluoglu B, Klinman DM (2021) CpG oligonucleotides as vaccine adjuvants. Methods Mol Biol 2197:51\u201385","journal-title":"Methods Mol Biol"},{"issue":"3","key":"9104_CR99","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.addr.2008.12.003","volume":"61","author":"AK Salem","year":"2009","unstructured":"Salem AK, Weiner GJ (2009) Cpg oligonucleotides as immunotherapeutic adjuvants: innovative applications and delivery strategies. Adv Drug Deliv Rev 61(3):193\u2013194","journal-title":"Adv Drug Deliv Rev"},{"key":"9104_CR100","doi-asserted-by":"publisher","unstructured":"Zhang Z, Kuo JC, Yao S, Zhang C, Khan H, Lee RJ (2021) Cpg oligodeoxynucleotides for anticancer monotherapy from preclinical stages to clinical trials. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics14010073","DOI":"10.3390\/pharmaceutics14010073"},{"issue":"1","key":"9104_CR101","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41541-021-00418-0","volume":"6","author":"DT O'Hagan","year":"2021","unstructured":"O\u2019Hagan DT, van der Most R, Lodaya RN, Coccia M, Lofano G (2021) \u201cWorld in motion\u201d: emulsion adjuvants rising to meet the pandemic Challenges. NPJ Vaccines 6(1):158","journal-title":"NPJ Vaccines"},{"issue":"3","key":"9104_CR102","doi-asserted-by":"publisher","first-page":"e24662","DOI":"10.1016\/j.heliyon.2024.e24662","volume":"10","author":"Z Huang","year":"2024","unstructured":"Huang Z, Gong H, Sun Q, Yang J, Yan X, Xu F (2024) Research progress on emulsion vaccine adjuvants. Heliyon 10(3):e24662","journal-title":"Heliyon"},{"key":"9104_CR103","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9020075","author":"Z Li","year":"2021","unstructured":"Li Z, Zhao Y, Li Y, Chen X (2021) Adjuvantation of influenza vaccines to induce cross-protective immunity. Vaccines. https:\/\/doi.org\/10.3390\/vaccines9020075","journal-title":"Vaccines"},{"issue":"5","key":"9104_CR104","doi-asserted-by":"publisher","first-page":"797","DOI":"10.2144\/96205bm14","volume":"20","author":"R Vulliet","year":"1996","unstructured":"Vulliet R (1996) Improved technique for the preparation of water-in-oil emulsions containing protein antigens. Biotechniques 20(5):797\u2013800","journal-title":"Biotechniques"},{"issue":"23","key":"9104_CR105","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1016\/j.vaccine.2019.04.048","volume":"37","author":"C Cohet","year":"2019","unstructured":"Cohet C, van der Most R, Bauchau V, Bekkat-Berkani R, Doherty TM, Schuind A et al (2019) Safety of AS03-adjuvanted influenza vaccines: a review of the evidence. Vaccine 37(23):3006\u20133021","journal-title":"Vaccine"},{"issue":"3","key":"9104_CR106","doi-asserted-by":"publisher","first-page":"e2329","DOI":"10.1002\/rmv.2329","volume":"33","author":"EO Murchu","year":"2023","unstructured":"Murchu EO, Comber L, Jordan K, Hawkshaw S, Marshall L, O\u2019Neill M et al (2023) Systematic review of the efficacy, effectiveness, and safety of MF59\u00ae adjuvanted seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals \u2265 18 years of age. Rev Med Virol 33(3):e2329","journal-title":"Rev Med Virol"},{"key":"9104_CR107","doi-asserted-by":"crossref","unstructured":"Goksoyr L, Funch AB, Okholm AK, Theander TG, de Jongh WA, Bonefeld CM, & Sander AF (2022) Preclinical efficacy of a capsid virus-like particle-based vaccine targeting il-1beta for treatment of allergic contact dermatitis. Vaccines (Basel) 10(5):828","DOI":"10.3390\/vaccines10050828"},{"issue":"2","key":"9104_CR108","doi-asserted-by":"publisher","first-page":"111","DOI":"10.18485\/meattech.2023.64.2.19","volume":"64","author":"VV Jankovi\u0107","year":"2023","unstructured":"Jankovi\u0107 VV, Velebit B, Laki\u0107evi\u0107 B, Mitrovi\u0107 R, Milojevi\u0107 L (2023) Major allergens \u2013 the big nine. Meat Technol 64(2):111\u2013115","journal-title":"Meat Technol"},{"issue":"2","key":"9104_CR109","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/all.15023","volume":"77","author":"O Pfaar","year":"2022","unstructured":"Pfaar O, Bousquet J, Durham SR, Kleine-Tebbe J, Larche M, Roberts G et al (2022) One hundred and ten years of allergen immunotherapy: a journey from empiric observation to evidence. Allergy 77(2):454\u2013468","journal-title":"Allergy"},{"issue":"1","key":"9104_CR110","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/all.13266","volume":"73","author":"A Bonertz","year":"2018","unstructured":"Bonertz A, Roberts GC, Hoefnagel M, Timon M, Slater JE, Rabin RL et al (2018) Challenges in the implementation of EAACI guidelines on allergen immunotherapy: a global perspective on the regulation of allergen products. Allergy 73(1):64\u201376","journal-title":"Allergy"},{"issue":"9","key":"9104_CR111","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1111\/all.14773","volume":"76","author":"G Paoletti","year":"2021","unstructured":"Paoletti G, Di Bona D, Chu DK, Firinu D, Heffler E, Agache I et al (2021) Allergen immunotherapy: the growing role of observational and randomized trial \u201creal-world evidence.\u201d Allergy 76(9):2663\u20132672","journal-title":"Allergy"},{"issue":"14","key":"9104_CR112","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1001\/jama.2021.15072","volume":"326","author":"NP Klein","year":"2021","unstructured":"Klein NP, Lewis N, Goddard K, Fireman B, Zerbo O, Hanson KE et al (2021) Surveillance for adverse events after COVID-19 mRNA vaccination. JAMA 326(14):1390\u20131399","journal-title":"JAMA"},{"issue":"1","key":"9104_CR113","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-61613-4","volume":"16","author":"Y Pan","year":"2025","unstructured":"Pan Y, Han Y, Zhou C, Zhao L, Zheng J, Ye X et al (2025) Evaluating the safety of XBB.1.5-containing COVID-19 mRNA vaccines asing a self-controlled case series study. Nat Commun 16(1):6514","journal-title":"Nat Commun"},{"key":"9104_CR114","doi-asserted-by":"publisher","first-page":"715844","DOI":"10.3389\/falgy.2021.715844","volume":"2","author":"MD McSweeney","year":"2021","unstructured":"McSweeney MD, Mohan M, Commins SP, Lai SK (2021) Anaphylaxis to Pfizer\/BioNTech mRNA COVID-19 vaccine in a patient with clinically confirmed PEG allergy. Front Allergy 2:715844","journal-title":"Front Allergy"}],"container-title":["Clinical Reviews in Allergy &amp; Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-025-09104-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-025-09104-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-025-09104-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T11:03:20Z","timestamp":1761131000000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-025-09104-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":114,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9104"],"URL":"https:\/\/doi.org\/10.1007\/s12016-025-09104-8","relation":{},"ISSN":["1559-0267"],"issn-type":[{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,22]]},"assertion":[{"value":"7 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"93"}}